Brigham Young University revealed on Thursday that its FDA listed alcohol-free Disinfect & Shield hand sanitizer containing benzalkonium chloride are just as effective against the COVID-19 virus as alcohol-based products based on a new research based study.
The new study was reportedly published in The Journal of Hospital Infection.
According to the university , the Disinfect & Shield Hand Sanitizer is available as a moisture-infused foam or spray that leaves an invisible, breathable barrier on the skin. It not only destroys 99.99% of bacteria but is also eco-friendly, making it ultra-safe for use around pets and plants while protecting the treated area for up to a full eight hours. The product is effective against numerous viruses, bacteria, moulds, and fungi enveloped and non- enveloped, including strains of SARS, MRSA and Staph infection.
Disinfect & Shield is a fast-acting nanotechnology that destroys viruses and bacteria and prevents them from attaching to skin, surfaces, and clothes. The colourless, odourless, positively charged polymer bonds to the treated surface creating a layer of electrically charged swords. They protect the surface from biofilm growth by puncturing the cell membrane. It is alcohol-free and eliminates the harsh fumes and cracked, dry skin that accompanies alcohol-based sanitizers and its safe for use on PPE like gloves, concluded the university.
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
PRISM BioLab partners with Talus Bioscience to address TF and PPI targets
Thryv Therapeutics reports positive Phase 1 results for THRV-1268